The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Understanding and Overcoming Major Barriers in Cancer Nanomedicine
Open accessAbstract
Cancer nanomedicine is currently under intense development for applications in cancer imaging, molecular diagnosis and targeted therapy [1–6]. The basic rationale is that nanometer-sized particles, such as quantum dots (QDs), colloidal gold and polymeric nanomicelles, have functional and structural properties that are not available from either discrete molecules or bulk materials [7–10]. When conjugated with targeting ligands such as monoclonal antibodies, peptides or small molecules, these nanoparticles can be used to target malignant tumor cells and the tumor microenvironment (e.g., tumor stroma and tumor vasculatures) with high specificity and affinity. In the ‘mesoscopic’ size range of 10 to 100 nm, nanoparticles also have large surface areas for conjugating to multiple diagnostic and therapeutic agents, opening up new possibilities in integrated cancer imaging and therapy. However, at present there are several fundamental problems and technical barriers that must be understood and overcome. These problems include nanoparticle surface opsonization (surface ‘fouling’ by nonspecific protein adsorption) [11–13], nanoparticle uptake and retention in reticuloendothelial organs (e.g., liver and spleen [14,15], difficulties in nanoparticle targeting and penetration in solid tumors [16,17], and the long-term fate and toxicity concerns of nanoparticles, especially nonbiodegradable nanomaterials containing toxic elements [18–20]. Thus, there is an urgent need to study these problems and to develop innovative strategies for overcoming them. In this article, we briefly discuss the major challenges and opportunities in developing cancer nanomedicine for molecular imaging, in vitro diagnostics and targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
In vivo cancer targeting and imaging with semiconductor quantum dots
Gao, X., Cui, Y., Levenson, R. M., Chung, L. W. K., & Nie, S. (2004) · Nature Biotechnology · doi:10.1038/nbt994 · Cited by 4,772
Self-citationCancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Cedervall, T., Lynch, I., Lindman, S., Berggård, T., Thulin, E., Nilsson, H., Dawson, K. A., & Linse, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608582104 · Cited by 3,281
The use of nanocrystals in biological detection
Alivisatos, P. (2004) · Nature Biotechnology · doi:10.1038/nbt927 · Cited by 3,008
Lundqvist, M., Stigler, J., Elia, G., Lynch, I., Cedervall, T., & Dawson, K. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805135105 · Cited by 2,823
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Nanoparticle and targeted systems for cancer therapy
Brannon-Peppas, L., & Blanchette, J. O. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.02.014 · Cited by 2,334
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
Immunological properties of engineered nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.223 · Cited by 1,823
Gref, R., Lück, M., Quellec, P., Marchand, M., Dellacherie, E., Harnisch, S., Blunk, T., & Müller, R. H. (2000) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00156-3 · Cited by 1,723
In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice
Liu, Z., Cai, W., He, L., Nakayama, N., Chen, K., Sun, X., Chen, X., & Dai, H. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2006.170 · Cited by 1,436
Nanomedicine—Challenge and Perspectives
Riehemann, K., Schneider, S. W., Luger, T. A., Godin, B., Ferrari, M., & Fuchs, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802585 · Cited by 1,305
Moghimi, S. M., & Szebeni, J. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00033-x · Cited by 1,227
In vivo Biodistribution and Highly Efficient Tumour Targeting of Carbon Nanotubes in Mice
Liu, Z., Cai, W., He, L., Nakayama, N., Chen, K., Sun, X., Chen, X., & Dai, H. (2020) · Nano-Enabled Medical Applications · doi:10.1201/9780429399039-14 · Cited by 1,213
In vivo molecular and cellular imaging with quantum dots
Gao, X., Yang, L., Petros, J. A., Marshall, F. F., Simons, J. W., & Nie, S. (2005) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2004.11.003 · Cited by 1,211
Self-citationBioconjugated quantum dots for in vivo molecular and cellular imaging☆
SMITH, A., DUAN, H., MOHS, A., & NIE, S. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.015 · Cited by 1,193
Self-citationTissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Girard, O. M., Hanahan, D., Mattrey, R. F., & Ruoslahti, E. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.013 · Cited by 1,136
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,125
Nanotechnology applications in cancer
Nie, S., Xing, Y., Kim, G. J., & Simons, J. W. (2007) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.9.060906.152025 · Cited by 952
Self-citationTumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers
Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj070 · Cited by 920
Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 803
Nanomedicine: Developing smarter therapeutic and diagnostic modalities☆
FAROKHZAD, O., & LANGER, R. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.011 · Cited by 800
Detailed Identification of Plasma Proteins Adsorbed on Copolymer Nanoparticles
Cedervall, T., Lynch, I., Foy, M., Berggård, T., Donnelly, S. C., Cagney, G., Linse, S., & Dawson, K. A. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700465 · Cited by 777
Parameters influencing the stealthiness of colloidal drug delivery systems
Vonarbourg, A., Passirani, C., Saulnier, P., & Benoit, J.-P. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.03.039 · Cited by 740
Transport of Molecules, Particles, and Cells in Solid Tumors
Jain, R. K. (1999) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.1.1.241 · Cited by 691
Detailed Identification of Plasma Proteins Adsorbed on Copolymer Nanoparticles
Cedervall, T., Lynch, I., Foy, M., Berggård, T., Donnelly, S. C., Cagney, G., Linse, S., & Dawson, K. A. (2007) · Angewandte Chemie · doi:10.1002/ange.200700465 · Cited by 655
Daniels, T. R., Delgado, T., Rodriguez, J. A., Helguera, G., & Penichet, M. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.010 · Cited by 634
Folate Receptor-Mediated Drug Targeting: From Therapeutics to Diagnostics
Hilgenbrink, A. R., & Low, P. S. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20457 · Cited by 625
Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.
Jain, R. K. (1990) · PubMed · Cited by 574
Nanotechnology Safety Concerns Revisited
Stern, S. T., & McNeil, S. E. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfm169 · Cited by 560
Seven challenges for nanomedicine
Sanhai, W. R., Sakamoto, J. H., Canady, R., & Ferrari, M. (2008) · Nature Nanotechnology · doi:10.1038/nnano.2008.114 · Cited by 538
The role of complement in inflammation and phagocytosis
Frank, M. M., & Fries, L. F. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90009-i · Cited by 503
Nanoparticles evading the reticuloendothelial system: Role of the supported bilayer
Li, S.-D., & Huang, L. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2009.06.022 · Cited by 486
Theranostic Nanomedicine for Cancer
Sumer, B., & Gao, J. (2008) · Nanomedicine · doi:10.2217/17435889.3.2.137 · Cited by 478
Roser, M., Fischer, D., & Kissel, T. (1998) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(98)00038-1 · Cited by 357
Gessner, A., Lieske, A., Paulke, B. R., & Müller, R. H. (2002) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(02)00081-4 · Cited by 356
Heath, J. R., & Davis, M. E. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.061506.185523 · Cited by 354
Does a targeting ligand influence nanoparticle tumor localization or uptake?
Pirollo, K. F., & Chang, E. H. (2008) · Trends in Biotechnology · doi:10.1016/j.tibtech.2008.06.007 · Cited by 347
Oh, P., Borgström, P., Witkiewicz, H., Li, Y., Borgström, B. J., Chrastina, A., Iwata, K., Zinn, K. R., Baldwin, R., Testa, J. E., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1292 · Cited by 300
Jain, R. K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00306-6 · Cited by 298
Uptake of dextran‐coated monocrystalline iron oxides in tumor cells and macrophages
Moore, A., Weissleder, R., & Bogdanov, A. (1997) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880070629 · Cited by 260
L�ck, M., Paulke, B.-R., Schr�der, W., Blunk, T., & M�ller, R. H. (1998) · Journal of Biomedical Materials Research · doi:10.1002/(sici)1097-4636(19980305)39:3<478::aid-jbm19>3.0.co;2-6 · Cited by 225
Xu, L., Pirollo, K. F., Tang, W.-H., Rait, A., & Chang, E. H. (1999) · Human Gene Therapy · doi:10.1089/10430349950016357 · Cited by 218
Minimizing the Hydrodynamic Size of Quantum Dots with Multifunctional Multidentate Polymer Ligands
Smith, A. M., & Nie, S. (2008) · Journal of the American Chemical Society · doi:10.1021/ja804306c · Cited by 206
Self-citationGaranger, E., Boturyn, D., & Dumy, P. (2007) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152007781668706 · Cited by 185
Cellular Dynamics of EGF Receptor–Targeted Synthetic Viruses
de Bruin, K., Ruthardt, N., von Gersdorff, K., Bausinger, R., Wagner, E., Ogris, M., & Bräuchle, C. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300176 · Cited by 168
Smith, A. M., & Nie, S. (2009) · Nature Biotechnology · doi:10.1038/nbt0809-732 · Cited by 167
Self-citationSelective gene delivery for cancer therapy using cationic liposomes: In vivo proof of applicability
Dass, C. R., & Choong, P. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.009 · Cited by 114
Cited by
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Gold nanoparticles in biomedical applications: recent advances and perspectives
Dykman, L., & Khlebtsov, N. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15166e · Cited by 1,961
Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
Walkey, C. D., Olsen, J. B., Guo, H., Emili, A., & Chan, W. C. W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2084338 · Cited by 1,926
Cell Membrane Coating Nanotechnology
Fang, R. H., Kroll, A. V., Gao, W., & Zhang, L. (2018) · Advanced Materials · doi:10.1002/adma.201706759 · Cited by 1,885
A review of NIR dyes in cancer targeting and imaging
Luo, S., Zhang, E., Su, Y., Cheng, T., & Shi, C. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.06.024 · Cited by 1,432
Metadata
- Authors
- Nie, S.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2010-06
- Volume
- 5
- Issue
- 4
- Pages
- 523-528
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2157770632
- Cited by
- 498
- References
- 53
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.